Iñiguez A, Chevalier B, Richardt G, et al. - Researchers used a prespecified subgroup of patients having multivessel coronary artery disease and participating in the CENTURY II trial, to determine the long-term safety as well as the efficacy of a sirolimus-eluting stent with bioresorbable polymer (BP-SES; Ultimaster), vs a benchmark everolimus-eluting, permanent polymer stent (PP-EES; Xience). In this substudy, the treatment arms had similar baseline patient, lesion and procedure features. Both BP-SES and PP-EES demonstrated low and comparable rates of target lesion failure, and definite or probable stent thrombosis, respectively, at 1 and 5 years. Experts also reported similarity in terms of the composite endpoint of cardiac mortality and myocardial infarction [MI], and the patient-oriented composite endpoint of any death, MI, and coronary revascularizations. Findings confirmed that the studied bioresorbable polymer stent has good long-term safety as well as efficacy in this high-risk patient population.